The U.S. Food and Drug Administration issued final guidance on November 2, 2026, explaining how cell and gene therapy manufacturers can plan for and verify product potency. The recommendations focus on checking that every batch meets a defined potency standard before it reaches a patient.
The announcement concerns product development and manufacturing quality, rather than approval of a particular treatment. It is especially relevant to manufacturers and developers, while also helping patients and caregivers understand the quality checks behind therapies for serious and often life-threatening conditions.
What the cell and gene therapy guidance changes
According to the FDA announcement, the final Potency Assurance for Cellular and Gene Therapy Products guidance replaces the agency’s 2011 potency testing guidance for these products.
The updated document describes a “Potency Assurance Strategy”: a comprehensive, science- and risk-based plan for making sure products meet potency standards. Rather than addressing potency only at one point, FDA recommends integrating it throughout development, manufacturing, and commercialization.
The agency says manufacturers are legally expected to verify that their products work as intended, from approval through post-approval monitoring. The guidance provides FDA’s current thinking and recommendations on meeting that requirement. The recommendations are intended to be flexible and risk-based, rather than a single approach for every product.
What potency testing is meant to establish
In this context, potency concerns whether a product is biologically active in a way that matches its intended therapeutic effect. The guidance describes laboratory tests that help confirm this activity and verify that each batch meets a defined standard.
These are product-quality checks. The announcement does not provide a way to predict how an individual patient will respond, nor does it recommend one therapy over another. Its focus is the manufacturer’s responsibility to verify the product’s potency before administration and continue verification after approval.
Quality checks across development and production
FDA’s recommendations extend from early-phase investigational new drug submissions through biologics license application approval and continued post-market verification. The announcement identifies three central areas:
- Raw materials: Controls to address variability in materials used to make a product.
- Manufacturing: Testing during production as part of the overall potency assurance strategy.
- Batch testing: Laboratory tests to confirm biological activity consistent with the intended therapeutic effect.
The guidance also addresses specialized considerations for products with short shelf lives, viral vector gene therapies, and patient-specific therapies. FDA notes that many patients receive products made individually for a single person, making these manufacturing considerations particularly relevant.
What patients, caregivers, and developers can take away
For patients and caregivers, the key point is that FDA is clarifying how manufacturers should demonstrate product potency. The announcement discusses therapies used for serious conditions, including cancers and rare diseases, and notes that some patients have no other treatment options.
FDA describes the clearer regulatory roadmap as supporting faster access to safe and effective therapies while maintaining quality standards. That is the agency’s stated aim; the announcement does not establish that any specific therapy will become available sooner.
For developers and manufacturers, the practical focus is planning for potency throughout the product’s lifecycle, including material controls, manufacturing tests, and continued verification. FDA also announced a webinar for December 10, 2026, to help stakeholders understand and implement the guidance.
The announcement does not offer patient-specific treatment advice. Questions about whether a particular therapy is appropriate, what benefit to expect, or how it fits with other care require discussion with the treating medical team rather than conclusions drawn from this manufacturing guidance.
Frequently Asked Questions
Does this guidance approve a new therapy?
No. The announcement describes final recommendations for potency assurance in cellular and gene therapy products, not approval of a specific treatment.
Does potency assurance end when a product is approved?
No. FDA describes an approach that begins during development and continues through approval and post-market verification.
Does the guidance address therapies made for one patient?
Yes. FDA says it includes specialized considerations for patient-specific therapies, along with products that have short shelf lives and viral vector gene therapies.
